Get Premium to unlock powerful stock data
Insmed Inc logo

Insmed Inc

$ 22.97 +0.91 (+4.13%) 09:50 AM EST
P/E:
At Loss
P/B:
22.06
Market Cap:
$ 2.65B
Enterprise V:
$ 2.84B
Volume:
136.78K
Avg Vol (2M):
1.20M
Also Trade In:
Volume:
136.78K
Market Cap $:
2.65B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.20M
Enterprise Value $:
2.84B
PB Ratio:
22.06
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Insmed Inc
NAICS : 325412 SIC : 2834
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Description
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Name Current Vs Industry Vs History
Cash-To-Debt 0.76
Equity-to-Asset 0.1
Debt-to-Equity 6.98
Debt-to-EBITDA -2.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.6
Distress
Grey
Safe
Beneish M-Score -2.12
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 76.7
9-Day RSI 68.09
14-Day RSI 61.8
6-1 Month Momentum % -28
12-1 Month Momentum % -32.18

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.04
Quick Ratio 5.52
Cash Ratio 5.07
Days Inventory 488.33
Days Sales Outstanding 38.22
Days Payable 253.37

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -15.4

Financials (Next Earnings Date:2022-08-05 Est.)

INSM's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:INSM

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 201.354
EPS (TTM) ($) -3.78
Beta 1.25
Volatility % 33.9
14-Day RSI 61.8
14-Day ATR ($) 1.172807
20-Day SMA ($) 19.537
12-1 Month Momentum % -32.18
52-Week Range ($) 16.41 - 34.435
Shares Outstanding (Mil) 119.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Insmed Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More